Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Volumn 14, Issue 5-6, 2013, Pages 397-405

  Beghi, Ettore ^a   Pupillo, Elisabetta ^a   Bonito, Virginio ^b   Buzzi, Paolo ^c   Caponnetto, Claudia ^d   Chiò, Adriano ^e   Corbo, Massimo ^f   Giannini, Fabio ^g   Inghilleri, Maurizio ^h   Bella, Vincenzo La ⁱ   Logroscino, Giancarlo ^j   Lorusso, Lorenzo ^k   Lunetta, Christian ^f   Mazzini, Letizia ^l   Messina, Paolo ^a   Mora, Gabriele ^m   Perini, Michele ⁿ   Quadrelli, Maria Lidia ^a   Silani, Vincenzo ^o   Simone, Isabella L ^j   Tremolizzo, Lucio ^p   Samarelli, Vito ^q   Tortelli, Rosanna ^q   D'Errico, Eustachio ^q   Merello, Maria ^q   Tavernelli, Fiorella ^q   Mancardi, Giovanni L ^q   Mascolo, Maria ^q   Bendotti, Caterina ^q   Buratti, Mariagrazia ^q   Floriani, Irene ^q   Giordano, Laura ^q   Giussani, Giorgia ^q   Maderna, Luca ^q   Maestri, Eleonora ^q   Marinou, Kalliopi ^q   Mennini, Tiziana ^q   Messina, Stefano ^q   Morelli, Cludia ^q   Papetti, Laura ^q   Rizzo, Aurora ^q   Ticozzi, Nicola ^q   Verde, Federico ^q   Ferrarese, Carlo ^q   Marzorati, Laura ^q   Testa, Lucia ^q   Valentino, Francesca ^q   Frasca, Vittorio ^q   Giacomelli, Elena ^q   Casa, Stefania ^q   Malentacchi, Maria ^q   Calvo, Andrea ^q   Cammarosano, Stefania ^q   Moglia, Cristina ^q   Cavallo, Enrico ^q   Fuda, Giuseppe ^q   more..

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c Unione Operative di Neurologia   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f OSPEDALE NIGUARDA CA GRANDA   (Italy)

^g UNIVERSITY OF SIENA   (Italy)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁱ UNIVERSITY OF PALERMO   (Italy)

^j UNIVERSITY OF BARI   (Italy)

^k UO Neurologia   (Italy)

^l MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

^m IRCCS   (Italy)

ⁿ Azienda Ospedaliera S Antonio Abate di Gallarate   (Italy)

^o ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^p SAN GERARDO HOSPITAL   (Italy)

^q NONE

more..

Author keywords

Acetyl L carnitine; Amyotrophic lateral sclerosis; Motor neuron disease; Randomized trial

Indexed keywords

LEVACECARNINE; PLACEBO; RILUZOLE;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FORCED VITAL CAPACITY; HUMAN; MALE; MCGILL PAIN QUESTIONNAIRE; MORTALITY; MULTICENTER STUDY; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

ACETYLCARNITINE; ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; MALE; MIDDLE AGED; NOOTROPIC AGENTS; PILOT PROJECTS; QUALITY OF LIFE; RILUZOLE; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84881322666     PISSN: 21678421     EISSN: 21679223     Source Type: Journal    
DOI: 10.3109/21678421.2013.764568     Document Type: Article

References (33)

1. Beghi E 1., Mennini T, Bendotti C, Bigini P, Logroscino G, Chi ò A, et al. The heterogeneity of amyotrophic lateral sclerosis: A possible explanation of treatment failure. Curr Med Chem. 2007 ; 14: 3185-200
2. Miller R G, Mitchell J D, Lyon M, Moore D H. R iluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2007;(1):CD001447
3. Virmani A, Binienda Z. R ole of carnitine esters in brain neuropathology. Mol Aspects Med. 2004 ; 25: 533-49
4. Bigini P, Larini S, Pasquali C, Muzio V, Mennini T. Acetyl-L-carnitine shows neuroprotective and neurotrophic activity in primary culture of rat embryo motor neurons. Neurosci Lett. 2002 ; 329: 334-8
5. Bigini P, Muzio V, de Angelis C, Mennini T. I n vitro and in vivo effect of acetyl-L-carnitine on motor neuron degeneration. Neurosci Lett. 1999; 52: S18
6. Bellingham MC. A review of the neural mechanisms of action and clinical effi ciency of riluzole in treating amyotrophic lateral sclerosis: What have we learned in the last decade? CNS Neurosci Ther. 2011 ; 17: 4-31
7. Miller R G, Munsat TL, Swash M, Brooks B R. C onsensus guidelines for the design and implementation of clinical trials in ALS. J Neurol Sci. 1999 ; 169: 2-12
8. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: A revised ALS functional rating scale that incorporates assessment of respiratory function. J Neurol Sci. 1999 ; 169: 13-21
9. Medical Research Council. A ids to the investigation of peripheral nerve injuries. War memorandum, 2nd edn. London: HMSO, 1943; 7: 11-46
10. Ware J, Sherbourne C. The MOS 36 item short-form survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 ; 30: 473-83
11. COSTART: Coding Symbols for Thesaurus of Adverse Reaction Terms. 5th edn. Rockville, Md: Food and Drug Administration; 1995. Publication FDA/CDER-95/24
12. The Italian ALS Study Group. B ranched-chain amino acids and amyotrophic lateral sclerosis: A treatment failure? Neurology. 1993 ; 43: 2466-70
13. Beghi E, Chiò A, Inghilleri M, Mazzini L, Micheli A, Mora G, et al. A randomized controlled trial of recombinant interferon beta-1a in ALS. Neurology. 2000 ; 54: 469-74
14. Steiner T. B ranched-chain amino acid in ALS. The European trial. In: Clifford RF, editor. New evidence MND/ALS research. London: Smith-Gordon; 1991. pp. 315-6
15. Messina P, Beghi E. Modelling drop-outs in amyotrophic lateral sclerosis. Contemp Clin Trials. 2012 ; 33: 218-22
16. Cudkowicz M, Bozik ME, Ingersoll E, Miller R, Mitsumoto H, Shefner J, et al. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med. 2011 ; 17: 1652-6
17. Rudnicki S A, Berry J D, Ingersoll E, Archibald D, Cudkowicz ME, Kerr DA, Dong Y. Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a phase II study: Subgroup analysis of demographic and clinical characteristics. Amyotroph Lateral Scler. 2013 ; 25: 44-51
18. Kimura F, Fujimura C, Ishida S, Nakajima H, Furutama D, Uehara H, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006 ; 66: 265-7
19. Bigini P, Muzio V, Pasquali C, Larini S, Ghirardi O, Mennini T. Acetyl-L-carnitine effect on motor neuron disease. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001: 2: 153
20. Ramirez C, Piemonte M E, Callegaro D, Da Silva H C. Fatigue in amyotrophic lateral sclerosis: Frequency and associated factors. Amyotroph Lateral Scler. 2008 ; 9: 75-80
21. McElhiney M C, Rabkin J G, Gordon P H, Goetz R, Mitsumoto H. Prevalence of fatigue and depression in ALS patients and change over time. J Neurol Neurosurg Psychiatry. 2009 ; 80: 1146-9
22. Lo Coco D, La Bella V. F atigue, sleep, and nocturnal complaints in patients with amyotrophic lateral sclerosis. Eur J Neurol. 2012 ; 19: 760-3
23. T omassini V, Pozzilli C, Onesti E, Pasqualetti P, Marinelli F, Pisani A, et al. Comparison of the effects of acetyl-Lcarnitine and amantadine for the treatment of fatigue in multiple sclerosis: Results of a pilot, randomized, doubleblind, crossover trial. J Neurol Sci. 2004 ; 218: 103-8
24. Plioplys A V, Plioplys S. A mantadine and L-carnitine treatment of chronic fatigue syndrome. Neuropsychobiology. 1997 ; 35: 16-23
25. Hart AM, Wilson AD, Montovani C, Smith C, Johnson M, Terenghi G, et al. Acetyl-L-carnitine: A pathogenesis based treatment for HIV-associated antiretroviral toxic neuropathy. AIDS. 2004 ; 18: 1549-60
26. Bianchi G, Vitali G, Caraceni A, Ravaglia S, Capri G, Cundari S, et al. Symptomatic and neurophysiological responses of paclitaxel-or cisplatin-induced neuropathy to oral acetyl-L-carnitine. Eur J Cancer. 2005 ; 41: 1746-50
27. de Grandis D. T olerability and Efficacy of acetyl-L-carnitine in patients with peripheral neuropathies: A short-term, open multicentre study. Clin Drug Invest. 1998 ; 15: 73-9
28. Gramignano G, Lusso M O, Madeddu C, Massa E, Serpe R, Deiana L, et al. Efficacy of L-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. Nutrition. 2006 ; 22: 136-45
29. Spagnoli LG, Palmieri G, Mauriello A, Vacha GM, D'Iddio S, Giorcelli G, et al. Morphometric evidence of the trophic effect of L-carnitine on human skeletal muscle. Nephron. 1990 ; 55: 16-23
30. Marin B, Desport J C, Kajeu P, Jesus P, Nicolaud B, Nicol M, et al. Alteration of nutritional status at diagnosis is a prognostic factor for survival of amyotrophic lateral sclerosis patients. J Neurol Neurosurg Psychiatry. 2011 ; 82: 628-34
31. Desport J C, Preux P M, Truong TC, Vallat J M, Sautereau D, Couratier P. Nutritional status is a prognostic factor for survival in ALS patients. Neurology. 1999 ; 53: 1059-63
32. Norris F H Jr, Calanchini PR, Fallat RJ, Panchari S, Jewett B. The administration of guanidine in amyotrophic lateral sclerosis. Neurology. 1974 ; 24: 721-8
33. Anonymous. A cetyl-L-carnitine monograph. A lternative Med Rev. 2010 ; 15: 76-83